PF-07104091 as a Single Agent and in Combination Therapy
Public ClinicalTrials.gov record NCT04553133. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.
Study identification
- NCT ID
- NCT04553133
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 157 participants
Conditions and interventions
Conditions
Interventions
- PF-07104091 monotherapy dose escalation Drug
- PF-07104091 + palbociclib + fulvestrant Drug
- PF-07104091 + palbociclib + letrozole Drug
- PF-07104091 monotherapy dose expansion (ovarian) Drug
- PF-07104091 monotherapy dose expansion (SCLC) Drug
- PF-07104091 + Fulvestrant (post CDK4/6) Drug
- PF-0704091 + Fulvestrant (post CDK4/6) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2020 (Actual)
- Primary completion
- Dec 31, 2026 (Estimated)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- May 6, 2026
2020 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Oncology & Hematology Associates DBA Mission Cancer and Blood | Clive | Iowa | 50325 | — |
| Des Moines Oncology Research Association | Des Moines | Iowa | 50309 | — |
| Medical Oncology & Hematology Associates DBA Mission Cancer and Blood | Des Moines | Iowa | 50309 | — |
| Medical Oncology & Hematology Associates DBA Mission Cancer and Blood | Des Moines | Iowa | 50314 | — |
| Norton Hospital | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Norton Cancer Institute, Audubon | Louisville | Kentucky | 40217 | — |
| Norton Brownsboro Hospital | Louisville | Kentucky | 40241 | — |
| Norton Cancer Institute, Brownsboro Campus | Louisville | Kentucky | 40241 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute - Chestnut Hill | Newton | Massachusetts | 02459 | — |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Cancer Center (IDS Pharmacy) | Long Island City | New York | 11101 | — |
| Laura & Isaac Perlmutter Cancer Center - NYU ACC | New York | New York | 10016 | — |
| NYU Langone Medical Center (Tisch Hospital) | New York | New York | 10016 | — |
| White Plains Hospital | White Plains | New York | 10601 | — |
| UVA Breast Care Center | Charlottesville | Virginia | 22911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04553133, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04553133 live on ClinicalTrials.gov.